Cerebrolysin

Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue through a controlled enzymatic hydrolysis process. The resulting compound is a mixture of low-molecular-weight peptide fragments and free amino acids, the most therapeutically significant of which can cross the blood-brain barrier. This capacity for central nervous system penetration distinguishes Cerebrolysin from many other neurological compounds and is central to its proposed mechanism of action.

The peptide mixture is believed to mimic the activity of endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF). These proteins regulate neuronal survival, synaptic plasticity, and the growth and maintenance of neurons throughout the brain. Because the peptide fragments in Cerebrolysin are small enough to cross the blood-brain barrier where full-sized growth factors cannot, researchers have investigated whether Cerebrolysin can effectively deliver neurotrophic signaling to the central nervous system.

Preclinical and clinical research has examined Cerebrolysin in the context of stroke recovery, traumatic brain injury (TBI), Alzheimer's disease, and general cognitive aging. A meta-analysis pooling six randomized, double-blind, placebo-controlled trials in mild-to-moderate Alzheimer's disease found Cerebrolysin was significantly more effective than placebo for cognitive function at four weeks ^[3], with effect sizes comparable to approved cholinesterase inhibitors. Research published in 2025 further explored its role in modulating secondary injury mechanisms following TBI, with investigators noting its potential to support neuronal survival and functional recovery.

Despite these findings, Cerebrolysin remains non-approved in the United States. A 2013 Cochrane review rated the overall evidence quality as very low, citing small sample sizes, short follow-up periods, high risk of bias, and predominantly manufacturer-funded studies. It is currently approved in a number of European and Asian countries for neurological indications. Researchers and clinicians working with Cerebrolysin in the United States treat it strictly as a research compound outside of any approved therapeutic context.